We are a patient-driven nonprofit dedicated to researching better therapies and a cure for angiosarcoma.
What is Angiosarcoma?
Clinical Trials
Events & Fundraisers
Research
Join the Angiosarcoma Project!
Angiosarcoma Awareness Inc has provided a $25k grant to the Broad Institute in order to obtain and ship living tumor samples from angiosarcoma patients to the Cancer Cell Line Factory
Angiosarcoma Awareness, July 2, 2021
Each cancer center may only see a small handful of patients with a given rare tumor a year, making the collection of living tissue samples—at the scale required to create laboratory cell […]
The Angiosarcoma Project in the News
Samantha Sullivan, September 30, 2018
The American Association for Cancer Research (AACR) issued the following press release focused on the Angiosarcoma Project, whose work is guided by Angiosarcoma Awareness, Inc.’s Vice President Dr. Corrie Painter. […]
New clinical trial is now recruiting in Boston
Samantha Sullivan, February 13, 2018
A new Phase II clinical trial targeting angiosarcoma is now recruiting patients at Boston’s Massachusetts General Hospital and the Dana-Farber Cancer Institute. For details on this and other available trials, […]
Presenting the We Will Prevail 5K!
Samantha Sullivan, January 30, 2018
After taking a year off for a strategic re-brand, we are excited to unveil the return of our community’s beloved 5K event, revamped for its 7th year, in its new […]
Recently Added

Phase II
A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma
Phase II
ADI- PEG 20 in Combination with Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma
Phase II
Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
All Clinical Trials
http://cancerres.aacrjournals.org/content/69/18/7175.long
Highlight

Current Research Project

Dr. Antonescu has drafted a budget based on a large scale genomic analysis of angiosarcoma tumors. Her current work has revealed that certain genes are upregulated in angiosarcomas even though there are no genetic mutations associated with the DNA that encodes those genes. The genes of interest are described in the manuscript linked below, many of which are involved in what would be considered “normal” angiogenesis. The fact that she has found them to be differentially regulated in angiosarcoma tumors has led to the hypothesis that there are epigenetic regulators of these genes that have yet to be identified through the genomic profiling applied to these studies thus far.

“Angiosarcoma Awareness combines patient advocacy with research funding.  The results of their efforts have led to numerous patients receiving care at sarcoma centers of excellence, and have translated into rapid progress in understanding this disease on a molecular level with respect to disease research.  Angiosarcoma Awareness provides a resounding voice for patients with angiosarcoma. We truly value our relationship with them and feel fortunate to have such a wonderful ally in our battle against this terrible disease. ”
Dr. William D. Tap, MD Chief
Sarcoma Medical Oncology Service
Memorial Sloan-Kettering Cancer Center
Close